-
Cancer Drug Use Declines After Negative Confirmatory Trials
15 Apr 2025 04:25 GMT
… cancer drugs with withdrawn US Food and Drug Administration … indications, idelalisib for follicular lymphoma, and romidepsin for … Among patients with follicular lymphoma, the use of … ineffective and potentially unsafe medications.”
SOURCE:
This study, …
-
The Evolving Landscape of Polycythemia Vera Treatment
15 Apr 2025 00:18 GMT
… .14 At this time, no drug therapy has been shown to … or refractory to HU. This drug may especially be useful in … intensity of treatment in polycythemia vera. N Engl J Med. 2013;368 … MPN-SAF patient cohorts. Leuk Lymphoma. 2017;58(6):1481-1487 …
-
HyBryte Achieves 75% Treatment Success by Week 18 in Ongoing CTCL Trial
14 Apr 2025 18:59 GMT
… .2022.2749
US Food and Drug Administration awards $2.6 million … HyBryte in the treatment of cutaneous T-cell lymphoma. Soligenix Inc. September … -hybrite-in-the-treatment-of-cutaneous-t-cell-lymphoma-301615684.html
Soligenix …
-
LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight Report to 2030: A $4 Billion+ Market Opportunity by 2030 - ResearchAndMarkets.com
14 Apr 2025 16:54 GMT
… amp; Regional Market Insight
Approved Drug Global & Regional Sales Analysis … Expected Completion Time For Key Drugs In Clinical Trials
The … a promising future for similar treatments and reflects the growing … 1 Cancer
5.1.1 Lymphoma
5.1.2 Melanoma
…
-
Fig the ferret fights off lymphoma
14 Apr 2025 15:45 GMT
… Cornell pathologists confirmed he had lymphoma, and a tumor had … remove the rest of the lymphoma.
Fig’s diagnosis was … grade, large-cell, alimentary lymphoma. Lymphoma is a common cancer in … diagnosis, there are reasonable treatment options that can improve the …
-
Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China
14 Apr 2025 14:59 GMT
… EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements … drugs in middle-income countries. This can help inform treatment choices and drug … trends, and determinants. Chinese Med J. 2022;135(5): … large-cell lymphoma in China. J Med Econ. 2022 …
-
EU approves Roche drug Columvi for lymphoma treatment
14 Apr 2025 13:45 GMT
More
World Expo: Swiss present robot-controlled wedding cake with edible battery
This content was published on
Apr 14, 2025
Confectioners and scientists from Switzerland and Italy and have created a robot-controlled, edible wedding cake, "RoboCake…
-
VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma
14 Apr 2025 13:00 GMT
… relapsed Hodgkin or non-Hodgkin lymphoma undergoing autologous hematopoietic cell transplant … and ability to advance innovative drug formulations that can improve … utilized in high-dose carmustine treatment for myeloablative conditioning. Forward-Looking …
-
Roche Columvi gets European Commission nod as bispecific antibody for diffuse large B-cell lymphoma after initial therapy
14 Apr 2025 12:53 GMT
… oxaliplatin (GemOx) for the treatment of adult patients with relapsed … R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified … (fast-growing) type of lymphoma and is one of the … an ‘’off-the-shelf’’ treatment regimen, readily available for infusion …
-
Approval moves Columvi earlier in DLBCL treatment pathway
14 Apr 2025 12:25 GMT
… for diffuse large B-cell lymphoma (DLBCL), the first in … death compared to the control treatment.
Columvi has already been … ) in second-line DLBCL treatment, which have complex manufacturing … that its drug uses a fixed duration of treatment, while AbbVie …
About
© 1995-2025